Clinical Trial Update: A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating atezolizumab with bevacizumab in untreated locally advanced or metastatic renal cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• atezolizumab + bevacizumab

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Renal Cell Carcinoma | Phase 3 | Status: WITHDRAWN